On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth quarter earnings report. The company registered U.S.

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

These Irish pubs have kept their doors open for centuries and proudly wear their age on their walls, all while serving up delicious pints of Guinness.

The new study estimated it would cost $173 million to implement all RUSP-approved conditions across all 50 states, including those added in late 2025 and two anticipated future conditions.

The theme of this year’s conference is “Supporting you every step of the way: from diagnosis to transplant.” Kidney Action Week is a highlight of Kidney Month, with four days of educational sessions ...

On March 1, the American Kidney Fund (AKF) will kick off Kidney Month by highlighting why Kidneys Count and how people can protect their kidney health. Kidney Month is observed every March and ...

The National Organization for Rare Disorders (NORD®) is calling attention to rare diseases as a significant and growing public health challenge affecting more than 30 million Americans. Fewer than 5 ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of John A. Orwin as Chair of its Board of Directors. Mr. Orwin succeeds Srinivas Akkaraju, M.D., Ph.D., ...

Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...